Please provide your email address to receive an email when new articles are posted on . Historically, patient-reported outcome measures were primarily used for research. Today, surgeons use ...
Analysis of the phase 3 explorer7 (NCT04083781) study indicates a preference for concizumab prophylaxis over no prophylaxis in patients with hemophilia A or B with inhibitors. Among individuals with ...
ChemR23 agonism targets inflammatory and neurosensory biology, with receptor expression on ocular immune cells and dorsal root ganglion neurons/glia supporting a mechanistic rationale for NCP symptom ...
SAN DIEGO, June 2, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from the Phase 4 KINECT-PROTM open-label study demonstrating robust and sustained ...
How can biotech companies use patient-reported outcomes to bring better drugs forward for patients? Generally, patient-reported outcomes (PROs) provide complementary information to measured or ...
OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye ...
There is a lack of systematic solutions to manage supportive care issues in racial/ethnic minorities (REM) receiving treatment for cancer. We developed and implemented an electronic patient-reported ...
Analysis of Patient Reported Outcomes From PATHFINDER Indicate Minimal Patient Distress Associated with Multi-Cancer Early Detection Testing MENLO PARK, Calif., Jan. 13, 2025 /PRNewswire/ -- GRAIL, ...
“It’s really hard to be a patient with cancer. Patients suffer a lot at home and don’t reach out,” Ethan Basch, MD, said. “Helping to have better communication to address their needs is really ...
Patient-reported outcomes (PROs) have rapidly become integral to cancer care, offering invaluable insights by capturing the patient’s perspective on symptoms, quality of life, and treatment-related ...
Most older adults with advanced cancer value quality of life over extending survival, but that preference may not translate to clinical care or outcomes.
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results